<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806468</url>
  </required_header>
  <id_info>
    <org_study_id>DEPOPA-2008</org_study_id>
    <nct_id>NCT00806468</nct_id>
  </id_info>
  <brief_title>Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease</brief_title>
  <acronym>DEPOPA</acronym>
  <official_title>A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to study the effect of Desmopressin on the nocturnal micturition
      frequency in patients with idiopathic Parkinson syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average nocturnal micturition frequency within the 2 weeks treatment phase each</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and efficacy on nocturnal micturition frequency of Desmopressin in patients with Parkinson syndrome</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Desmopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmotabs</intervention_name>
    <description>Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week</description>
    <arm_group_label>Desmopressin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients with idiopathic Parkinson Syndrome

          -  18 to 85 years

          -  Nocturnal Pollakisuria &gt; 2 mictions /night (documented in Screening phase )

          -  Na+ i.S &gt; 135 mmol/l

          -  Patient is able to understand all aspects and individual consequences of the clinical
             trial

          -  An informed consent signed and dated by the patient is available prior to any study
             specific treatment

          -  The study is consistent with the patients´ request for an appropriate treatment

        Exclusion Criteria:

          -  Intake of the following concomitant medication: Carbamazepin, Oxcarbazepine, diuretics
             (Furosemide, Torasemide), non steroidal antiphlogistics, Loperamide, antidiuretic
             hormone analoga (besides study medication), drugs for treatment of bladder
             disfunction, in particular anticholinergics

          -  Central Diabetes insipidus

          -  Known heart insufficiency (NYHA Stad. III und IV)

          -  clinical relevant kidney insufficiency

          -  Habitual and psychogenic Polydipsia

          -  Hypersensitivity or allergy against the trial medication or any other ingredient of
             the trial medication

          -  Participation in another clinical trial during or within 6 months prior to this
             clinical trial

          -  Medical or psychological condition, which might endanger the proper conduction of the
             clinical trial

          -  Known drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Vogt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University Mainz, Department of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg-Universität Mainz, Studienzentrum Neurologie, Langenbeckstr. 1, 55131 Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>December 17, 2010</last_update_submitted>
  <last_update_submitted_qc>December 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Thomas Vogt</name_title>
    <organization>Johannes Gutenberg University Mainz, Department of Neurology</organization>
  </responsible_party>
  <keyword>nycturia</keyword>
  <keyword>Parkinson syndrome</keyword>
  <keyword>desmopressin</keyword>
  <keyword>Nocturnal polyuria in patients with Parkinson syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

